Evidence map›Paper›PMID 30811590›Full record

ArticleCancer2019

Treatment capacity required for full-scale implementation of lung cancer screening in the United States.

Erik F Blom, Kevin Ten Haaf, Douglas A Arenberg, Harry J de Koning

Abstract read
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. The accuracy of administrative data in identifying pulmonary metastases: a population-based study in Northern Italy.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026
    Article
  3. Article
  4. Natural history models for lung Cancer: A scoping review.Lung cancer (Amsterdam, Netherlands) · 2025
    Article
  5. Current Evidence for a Lung Cancer Screening Program.Portuguese journal of public health · 2024
    Review
  6. The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations.Medical decision making : an international journal of the Society for Medical Decision Making · 2024
    Article
  7. Article
  8. How will lung cancer screening and lung nodule management change the diagnostic and surgical lung cancer landscape?European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Lung cancer screening in Europe: where are we in 2021?Translational lung cancer research · 2021
    Review
  18. Review
  19. Article
  20. Update on screening for lung cancer.Translational lung cancer research · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Erik F BlomDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-2016-5668
Kevin Ten HaafDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
Douglas A ArenbergDivision of Pulmonary & Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.
Harry J de KoningDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.

Funding

Comparative Modeling of Lung Cancer Prevention and Control PoliciesU01CA199284 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2015 to 2019
$8.4M
NCI NIH HHS U01 CA199284
6 · The paper itself

Abstract

backgroundFull-scale implementation of lung cancer screening in the United States will increase detection of early stages. This study was aimed at assessing the capacity required for treating those cancers.

methodsA well-established microsimulation model was extended with treatment data from the National Cancer Database. We assessed how treatment demand would change when implementing lung cancer screening in 2018. Three policies were assessed: 1) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 80 years, with a smoking history of at least 30 pack-years (US Preventive Services Task Force [USPSTF] recommendations); 2) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 77 years, with a smoking history of at least 30 pack-years (Centers for Medicare and Medicaid Services [CMS] recommendations); and 3) annual screening of current smokers and former smokers who quit fewer than 10 years ago, aged 55 to 75 years, with a smoking history of at least 40 pack-years (the most cost-effective policy in Ontario [Ontario]). The base-case screening adherence was a constant 50%. Sensitivity analyses assessed other adherence levels, including a linear buildup to 50% between 2018 and 2027.

resultsThe USPSTF policy would require 37.0% more lung cancer surgeries in 2015-2040 than no screening, 2.2% less radiotherapy, and 5.4% less chemotherapy; 5.7% more patients would require any therapy. The increase in surgical demand would be 96.1% in 2018, 46.0% in 2023, 38.3% in 2028, and 24.9% in 2040. Adherence strongly influenced results. By 2018, surgical demand would range from 52,619 (20% adherence) to 96,121 (80%). With a gradual buildup of adherence, the increase in surgical demand would be 9.6% in 2018, 38.3% in 2023, 42.0% in 2028, and 24.4% in 2040. Results for the CMS and Ontario policies were similar, although the changes in comparison with no screening were smaller.

conclusionsFull-scale implementation of lung cancer screening causes a major increase in surgical demand, with a peak within the first 5 years. A gradual buildup of adherence can spread this peak over time. Careful surgical capacity planning is essential for successfully implementing screening.

Indexed as

Computer SimulationHealth Plan ImplementationHealth PlanningAgedEarly Detection of CancerFemaleFollow-Up StudiesHumansIncidenceLung NeoplasmsMaleMiddle AgedPrognosisSmokingUnited Statesearly detection of cancerhealth resourceshealth workforcelung neoplasmstherapy

Identifiers

PMID30811590
PMCPMC6541509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.